en · de · es
lab-handbook.peptides6823.com › News › Identity And Research Background — 2026 Update

Identity And Research Background — 2026 Update

By Editorial Desk · published 2025-08-02 · last reviewed 2025-09-01 · News

A practical reference on thymosin beta-4 fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.

Identity and Research Background

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Identity and Physical Form

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

TB-500 Identity and Chemical Background

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Related pages on this site

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Reference notes

== Side effects == Side effects at lower doses include mild gastrointestinal discomfort and dizziness. Because decozine has mixed agonist/antagonist effects at the opioid receptors, it has a lowered dependence potential than purely agonistic opioids. It can be prescribed, therefore, in small doses over an extended period of time without causing patients to develop and sustain an addiction. Its efficacy as an analgesic is dose-dependent; however, it displays a ceiling effect in induced respiratory depression at 0.3 to 0.4 mg/kg.

Gas chromatography-mass spectrometry (GC-MS) can measure changes in the concentration of such solvents over time, allowing forensic analysts to estimate the relative age of some ink marks and potentially assess the chronology of entries in a document.

{\displaystyle {\ce {^{239}_{94}Pu ->[{\ce {(n,\gamma)}}] ^{240}_{94}Pu ->[{\ce {(n,\gamma)}}] ^{241}_{94}Pu ->[\beta^-][14.35\ {\ce {yr}}] ^{241}_{95}Am}}\ \left({\ce {->[\alpha][432.2\ {\ce {yr}}] ^{237}_{93}Np}}\right)}

Sources: en.wikipedia.org

Reference notes

Lifeson as a guitarist is best known for his signature riffing, electronic effects and processing, unorthodox chord structures, and a copious arsenal of equipment used over the years. During his adolescent years, he was influenced by Jimi Hendrix, Pete Townshend, Jeff Beck, Eric Clapton and Jimmy Page. Lifeson incorporated touches of Spanish and classical music into Rush's sound during the 1970s, reflecting his interest in progressive rock guitarists like Steve Hackett and Steve Howe. Adapting to Lee's expanding use of synthesizers in the 1980s, Lifeson took inspiration from guitarists like Allan Holdsworth, Andy Summers of The Police and The Edge of U2, who gave him models for rethinking the guitar's role in Rush's music. Lifeson's guitar returned to the forefront in the 1990s, and especially on Vapor Trails (2002). During live performances, he was responsible for cuing various guitar effects, the use of bass-pedal synthesizers and backing vocals. He occasionally has played keyboard synthesizers live.

The double “A” refers to the nickname “All American Division” adopted by the organization during World War I. The newly formed unit was composed of members, who came from all across all 48 states and given the nickname “All-American.” The shoulder sleeve insignia was redesigned for the 82nd Airborne Division and an Airborne tab was added on top, authorized on August 31, 1942.

Human iron homeostasis is regulated at two different levels. Systemic iron levels are balanced by the controlled absorption of dietary iron by enterocytes, the cells that line the interior of the intestines, and the uncontrolled loss of iron from epithelial sloughing, sweat, injuries and blood loss. In addition, systemic iron is continuously recycled. Cellular iron levels are controlled differently by different cell types due to the expression of particular iron regulatory and transport proteins.

It also scared NASA planners, as it took them several days to figure out that it was only an automated flight, not piloted, because voice recordings were transmitted from the craft en route to the Moon. On November 10, 1968, another automated test flight, Zond 6, was launched. It encountered difficulties in Earth reentry, and depressurized and deployed its parachute too early, causing it to crash-land only 16 kilometers (9.9 mi) from where it had been launched six days earlier. It turned out there was no chance of a piloted Soviet circumlunar flight during 1968, due to the unreliability of the Zonds. On December 21, 1968, Frank Borman, James Lovell, and William Anders became the first humans to ride the Saturn V rocket into space, on Apollo 8. They also became the first to leave low-Earth orbit and go to another celestial body, entering lunar orbit on December 24. They made ten orbits in twenty hours, and transmitted one of the most watched TV broadcasts in history, with their Christmas Eve program from lunar orbit, which concluded with a reading from the biblical Book of Genesis. Two and a half hours after the broadcast, they fired their engine to perform the first trans-Earth injection to leave lunar orbit and return to the Earth. Apollo 8 safely landed in the Pacific Ocean on December 27, in NASA's first dawn splashdown and recovery. The American Lunar Module was finally ready for a successful piloted test flight in low Earth orbit on Apollo 9 in March 1969.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Network